63610-08-2

Basic information

• Product Name: Indobufen
• Synonyms: (+-)-butyricaci;1-oxo-2-(p-((alpha-ethyl)carboxymethyl)phenyl)isoindoline;4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-benzeneaceticacid;INDOBUFEN;2-[4-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PHENYL]-BUTYRIC ACID;lndobufen;INDOBNFEN;2-[4-(1-oxo-2-isoindolinyl)phenyl]butyric acid
• CAS NO: 63610-08-2
• Molecular Formula: C₁₈H₁₇NO₃
• Molecular Weight: 295.33
• EINECS: 264-364-4
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 63610-08-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 182-184°
• Boiling Point: 518.1 °C at 760 mmHg
• Flash Point: 267.1 °C
• Appearance: /
• Density: 1.275 g/cm³
• Vapor Pressure: 1.47E-11mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.39±0.10(Predicted)
• CAS DataBase Reference: Indobufen(CAS DataBase Reference)
• NIST Chemistry Reference: Indobufen(63610-08-2)
• EPA Substance Registry System: Indobufen(63610-08-2)

Safety Data

• Hazardous Substances Data: 63610-08-2(Hazardous Substances Data)

Usage

Description

Indobufen is a platelet aggregation inhibitor related to the antiinflammatory agent indoprofen. It has shown clinical efficacy in peripheral artery disease, in prevention of deep vein thrombosis after myocardial infarction, and in blocking excercise-induced increase in platelet aggregation in angina patients.

Uses

Indobufen is a platelet aggregation inhibitor. Indobufen is the anticoagulant drug and platelet aggregation inhibitor, which has anti-inflammatory analgesic effect. Indobufen is used as an antithrombotic.

Brand name

IBUSTRIN

Clinical Use

A reversible but very potent inhibitor of platelet COX-1 activity, was shown to have comparable clinical efficacy to that of aspirin in prevention of DVT after myocardial infarction and in blocking exercise-induced increase in platelet aggregation. In the secondary prevention of thromboembolic events, 100 or 200 mg of indobufen twice daily is as effective as warfarin or aspirin in patients with or without atrial fibrillation. Currently, indobufen is only available for routine clinical use in Europe.

InChI:InChI=1/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)/t15-/m1/s1

Upstream product

• 943742-86-7 C₁₂H₁₅BrO₂ 
• 496-12-8 isoindoline 
• 2826-24-6 4-bromobenzylidenemalononitrile 
• 36691-01-7 ethyl 2-(4-(1-oxoisoindolin-2-yl)phenyl)acetate 
• 36691-02-8 ethyl 2-(4-(1-oxoisoindolin-2-yl)phenyl)butanoate 
• 100-39-0 benzyl bromide 
• 5438-70-0 ethyl (4-amino-3,5-dibromophenyl)acetate 
• 57960-76-6 ethyl 2-(4-(benzylamino)phenyl)acetate 
• 94232-67-4 2-[4-(1,3-dioxo-2-isoindolinyl)phenyl]butyric acid 
• 7463-53-8 2RS-(4-nitrophenyl)butanoic acid 

Relevant articles and documents

α-Angelica Lactone in a New Role: Facile Access to N-Aryl Tetrahydroisoquinolinones and Isoindolinones via Organocatalytic α-CH2 Oxygenation

A method for the direct oxidation of various N-aryl tetrahydroisoquinolines and isoindolines to the corresponding lactams using α-angelica lactone as a catalyst was developed. The utility of the method was further demonstrated by synthesis of indoprofen and indobufen.

Microtubing-Reactor-Assisted Aliphatic C?H Functionalization with HCl as a Hydrogen-Atom-Transfer Catalyst Precursor in Conjunction with an Organic Photoredox Catalyst

Chlorine radical, which is classically generated by the homolysis of Cl2 under UV irradiation, can abstract a hydrogen atom from an unactivated C(sp3)?H bond. We herein demonstrate the use of HCl as an effective hydrogen-atom-transfer catalyst precursor activated by an organic acridinium photoredox catalyst under visible-light irradiation for C?H alkylation and allylation. The key to success relied on the utilization of microtubing reactors to maintain the volatile HCl catalyst. This photomediated chlorine-based C?H activation protocol is effective for a variety of unactivated C(sp3)?H bond patterns, even with primary C(sp3)?H bonds, as in ethane. The merit of this strategy is illustrated by rapid access to several pharmaceutical drugs from abundant unfunctionalized alkane feedstocks.

Method for preparing indobufen

The invention discloses a method for preparing indobufen; by optimizing the processes such as using a carbon-supported noble metal as a catalyst in hydrogenation reduction, using a suitable organic acid solvent in zinc powder reduction and introducing hydrogen chloride gas, the preparation method of indobufen is simple to perform and high in yield; the whole preparation method is good in safety, environmentally friendly, good for protecting the health of workers and suitable for industrial use, and the purity of prepared indobufen is high.